Pulmatrix, Inc.
PULM · XNASCIK 1574235fmd_0130C1JZDXT4A0SET6XFTZT4JMManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2026, 53 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1 | 0 | 0 | 8 | 13 | 5 | 6 | 7 | 8 | – |
| Net interest income | – | – | – | – | 0 | 0 | 0 | 1 | 0 | – |
| Research and development | 10 | 10 | 13 | 13 | 16 | 15 | 18 | 16 | 7 | 0 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | – | – |
| Total operating expenses | 26 | 18 | 21 | 29 | 22 | 25 | 25 | 22 | 18 | 5 |
| Operating income | (25) | (17) | (20) | (21) | (10) | (20) | (19) | (15) | (10) | (5) |
| Interest expense | 1 | 1 | 0 | – | – | – | – | – | – | – |
| Interest and investment income | – | – | 0 | 0 | 0 | – | – | – | 0 | 0 |
| Other non-operating income (expense) | (0) | (1) | (0) | 0 | (9) | (0) | 0 | 1 | 0 | 0 |
| Income before taxes | (31) | (18) | – | – | – | – | – | – | – | – |
| Income tax expense | (3) | – | – | – | – | – | – | – | – | 0 |
| Net income from continuing operations | (28) | – | – | – | – | – | – | – | – | – |
| Net income | (28) | (18) | (21) | (21) | (19) | (20) | (19) | (14) | (10) | (5) |
| Net income to common shareholders | (28) | – | – | – | (19) | (23) | (19) | – | – | – |